Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-04-09
2008-10-14
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387500, C530S387700, C530S388850, C424S133100, C424S141100, C424S143100, C424S156100, C435S069600
Reexamination Certificate
active
07435797
ABSTRACT:
The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains
REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5837234 (1998-11-01), Gentile et al.
patent: 2002/0035736 (2002-03-01), Erickson et al.
patent: WO 92/20798 (1992-11-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/21319 (1993-10-01), None
patent: WO 94/00136 (1994-01-01), None
patent: WO 94/22478 (1994-10-01), None
patent: WO 96/16673 (1996-06-01), None
patent: WO 03/068801 (2003-08-01), None
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979.
(Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”).
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982).
Casset et al. ((2003) BBRC 307, 198-205).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Colman et al (Research in Immunology 1994, 145:33-36).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Bendig M. M. 1995. Methods: A Companion to Methods in Enzymology, 8:83-93.
Aasland et al., “Expression of oncogenes in thyroid tumours: coexpression of c-erbB2
euand c-erbB”,Br. J. Cancer, 57:358-363 (1988).
Arteaga et al., “p185c-erbB-2signaling enhances cisplatin-induced cytotoxicity in human breat carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair”,Cancer Res., 54:3758-3765 (1994).
Bacus et al., “Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2
euantigen”,Molecular Carcinogenesis, 3:350-362 (1990).
Bacus et al., “Tumor-inhibitory monoclonal antibodies to the HER-2
eu receptor induce differentiation of human breast cancer cells”,Cancer Research, 52:2580-2589 (1992).
Borst et al., “Oncongene alterations in endometrial carcinoma”,Gynecol. Oncol., 38:364-366 (1990).
Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy”,Proc. Nat. Acad. Sci. USA89: 4285-4289 (1992).
Chothia et al., “Conformations of immunoglobulin hypervariable regions”,Nature, 342(6252):877-83 (1989).
Cobleigh et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastic disease”,J Clin. Oncol., 17:2639-2648 (1999).
Cohen et al., “Expression pattern of theneu(NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract,”Oncogene, 4:81-88 (1989).
D'souza et al., “Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene”,Proc. Natl. Acad. Sci., 91:7202-7206 (1994).
Drebin et al., “Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies”,Cell, 41:695-706 (1985).
Drebin et al., “Monoclonal antibodies reactive with distinct domains of theneuoncongene-encoded p185 molecule exert synergistic anti-tumor effects in vivo”,Oncogene, 2:273-277 (1988).
Eigenbrot et al., “X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2antibody 4D5 and comparison with molecular modeling”,J Mol Bio, 229(4):969-95 (1993).
Fendly et al., “Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2
eugene product”,Cancer Res., 50(5):1550-8 (1990).
Fukushigi et al., “Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line”,Mol Cell Biol., 6:955-958 (1986).
Gallivan, J. P. & Dougherty, D. A., “Cation-π interactions in structural biology”,Proc Natl. Acad. Sci. USA, 96(17):9459-64 (1999).
Gu et al., “Overexpression of her-2
euin human prostate cancer and benign hyperplasia”,Cancer Lett., 99:185-9 (1996).
Geurin et al., “Overexpression of either c-mycor c-erbB-2
eupro-oncogenes in human breast carcinomas: correlations with poor prognosis”,Oncogene Res., 3:21-31 (1988).
Hancock et al., “A monoclonal antibody against the c-erbB-2 protein enhances the cytoxicity ofcis-diamminedichloroplatinum against human breast and ovarian tumor cell”,Cancer Res., 51:4575-4580 (1991).
Harwerth et al., “Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists”,J Biol. Chem., 267:15160-15167 (1992).
Holmes et al., “Identification of hergulin, a specific activator of p185erbB2”,Science, 256:1205-1210 (1992).
Hudziak et al., “p185HER2monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor”,Mol Cell Biol. 9(3):1165-72 (1989).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”,Nature, 321:522-525 (1986).
Kasprzyk et al., “Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies”,Cancer Research, 52:2771-2776 (1992).
Kelley et al., “Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2antibody fab fragments”,Biochemistry, 31(24):5434-411, (1992).
Kelley, R.F. & O'Connell, M.P., “Thermodynamic analysis of an antibody functional epitope”,Biochemistry, 32(27):6828-35 (1993).
Kern et al., “p185neuexpression in human lung adenocarcinomas predicts shortened survival”,Cancer Res., 50:5184-5191 (1990).
King et al., Amplification of a novel v-erbB-related gene in a human mammary carcinoma:,Science, 229:974-976 (1985).
Klapper et al. , “A subclass of tumor-inhibitory monoclonal antibodies to erbB-2/HER2 blocks crosstalk with growth factor receptors”,Oncogene, 14:2099-2109 (1997).
Kotts et al., “Differential growth inhibition of human carcinoma cells exposed to monoclonal antibodies directed against the extracellular domain of the HER2/ERBB2 protooncongene”, In Vitro, 26(3):59A (1990).
Kumar et al., “Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells”,Mol. Cell. Biol., 11(2):979-986 (1991).
Lewis et al., “Differential responses of human tumor cell lines to anti-p185HER2monoclonal antibodies”,Cancer Immunol. Immunother., 37:255-263 (1993).
Lewis et al., “Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of erbB2 as a critical component in mediating heregulin responsiveness”,Cancer Research, 56:1457-1465 (1996).
Lowman, H. B., “Phage display of peptide libraries on protein scaffolds”,Methods Mol Biol, 87:249-64 (1998).
Maier et al., “Requirements for the internalization of a murine monoclonal antibody directed against the HER-2
eugene product c-erbB-2”,Cancer Res., 51:5361-5369 (1991).
Marchionni et al., “Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system”,Nature, 362:312-318 (1993).
McCann et al., “c-erbB-2 oncoprotein expression in primary human tumors”,Cancer, 65:88-92 (1990).
McKeage, K. & Perry, C. M., “Trastuzumab: a review of its use in the treatment of metastatic brea
Carter Paul J.
Gerstner Resi B.
Lowman Henry B.
Agarwal Atulya R.
Blanchard David J.
Dreger, Esq. Ginger R.
Genentech Inc.
Goodwin & Procter LLP
LandOfFree
Anti-HER2 antibody variants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-HER2 antibody variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-HER2 antibody variants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993134